Rist B, Entzeroth M, Beck-Sickinger A G
Department of Pharmacy, ETH Zürich, Zürich, Switzerland.
J Med Chem. 1998 Jan 1;41(1):117-23. doi: 10.1021/jm970533r.
CGRP Y0-28-37 is known as a selective CGRP1 receptor antagonist. In order to elucidate the essential requirements for its receptor interaction, we performed a variety of systematic approaches by modifying the C-terminal segments CGRP Y0-28-37 and CGRP 27-37. N-Terminal and C-terminal segments have been synthesized, as well as chimeras which combine segments of CGRP, adrenomedullin, and amylin. Furthermore, we carried out an Ala scan, a Phe scan, a D-amino acid scan and a Pro scan of CGRP 27-37. Additionally, single amino acids were replaced by those with similar biophysical properties. Receptor binding studies of all analogs were performed at human neuroblastoma cells SK-N-MC, which selectively express the hCGRP1 receptor. On the basis of the obtained results, we synthesized a series of ligands with multiple amino acid replacements in order to optimize the exchange at each position. This approach yielded to a series of high affinity ligands, including [D31,P34,F35] CGRP 27-37 which exhibits a 100-fold increased affinity compared to the unmodified segment. So far, this is the smallest CGRP analog that shows affinity in the nanomolar range.
CGRP Y0-28-37被认为是一种选择性CGRP1受体拮抗剂。为了阐明其与受体相互作用的基本要求,我们通过修饰CGRP Y0-28-37和CGRP 27-37的C末端片段进行了各种系统的方法。合成了N末端和C末端片段,以及结合了CGRP、肾上腺髓质素和胰淀素片段的嵌合体。此外,我们对CGRP 27-37进行了丙氨酸扫描、苯丙氨酸扫描、D-氨基酸扫描和脯氨酸扫描。另外,单个氨基酸被具有相似生物物理性质的氨基酸所取代。所有类似物的受体结合研究在选择性表达hCGRP1受体的人神经母细胞瘤细胞SK-N-MC上进行。基于获得的结果,我们合成了一系列具有多个氨基酸替换的配体,以优化每个位置的交换。这种方法产生了一系列高亲和力配体,包括[D31,P34,F35] CGRP 27-37,其与未修饰片段相比亲和力增加了100倍。到目前为止,这是在纳摩尔范围内显示亲和力的最小CGRP类似物。